Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02607735 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

A Phase 3 study of Hepatitis C, sponsored by Gilead Sciences.

Completed
Registry status
Phase 3
Development phase
416
Enrollment target
20
Study locations

NCT02607735: Completed Phase 3 study of Hepatitis C, sponsored by Gilead Sciences.

NCT02607735 is a Phase 3 study of Hepatitis C that has completed, run by Gilead Sciences. The registered enrollment target is 416 participants, below the 1,886-participant average among 106 other Hepatitis C trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02607735, a Phase 3 study of Hepatitis C, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 3
Development phase
416 participants
Enrollment target
20
Study locations

Study Summary

The primary objectives of this study are to evaluate the safety and efficacy of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C virus (HCV) infection who have previously received treatment with direct-acting antiviral therapy. Participants randomized to placebo may be eligible for deferred treatment with active SOF/VEL/VOX.

Primary Outcome

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment.

Conditions Studied

Hepatitis C

Interventions

  • DRUG Placebo
  • DRUG SOF/VEL/VOX

Study Locations (20)

California

  • - Long Beach
  • - Los Angeles
  • - Palo Alto
  • - Pasadena
  • - Rialto
  • - San Diego
  • - San Francisco

Florida

  • - Gainesville
  • - Miami
  • - Orlando
  • - Wellington

Colorado

  • - Aurora
  • - Englewood

Georgia

  • - Atlanta
  • - Marietta

Maryland

  • - Baltimore
  • - Catonsville

District of Columbia

  • - Washington D.C.

Illinois

  • - Chicago

Indiana

  • - Indianapolis

Trial Details

FieldValue
Enrollment Target 416 participants
Start Date 2015-11-11
Est. Completion 2017-06-21
Phase Phase 3
Gilead Sciences

504 total trials

What the finished NCT02607735 record still lists

NCT02607735 is an interventional study that assigns participants to a tested intervention. The registered 416 participants enrollment target is mid-sized for trials with a published cap, below the 1,886-participant average among 106 other Hepatitis C trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02607735 names 20 study sites across 8 states, led by California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT02607735 about?

NCT02607735 is a clinical study titled "Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy". The primary objectives of this study are to evaluate the safety and efficacy of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C virus (HCV) infection who have previously received treatment with direct-acting antiviral therapy. Participants randomi...

What is the current status of trial NCT02607735?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2015-11-11. Estimated completion is 2017-06-21.

What conditions does trial NCT02607735 study?

This clinical trial studies the following conditions: Hepatitis C.

What interventions are being tested in trial NCT02607735?

The interventions under investigation include: Placebo (DRUG), SOF/VEL/VOX (DRUG).

Who is sponsoring clinical trial NCT02607735?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02607735 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02607735's enrollment target sits among peer trials

416 25th of 106 higher than 82 of 106 other Hepatitis C trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03527537 · 416 participants · Phase 4

    Gestational Diabetes and Pharmacotherapy (GAP)

  • NCT05007782 · 416 participants · Phase 1

    Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

  • NCT05520099 · 416 participants

    Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

  • NCT06075745 · 416 participants · Phase 2

    Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02607735, the US trial registry maintained by the National Library of Medicine. NCT02607735 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.